Search research articles
Contact Us
Filters
Showing results (211-220 of 257) with videos related to
Page
of 26
Sort By:
Cancer Cell
|
March 12, 2021
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Kevin Bi, Meng Xiao He, Ziad Bakouny, et al.
Cancer Discovery
|
February 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Miya B Hugaboom, Lena V Wirth, Kelly Street, et al.
Molecular Cancer
|
March 16, 2024
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects
Yufei Wang, Alicia Buck, Brandon Piel, et al.
Cancer Cell
|
June 10, 2025
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Kevin Bi, Meng Xiao He, Ziad Bakouny, et al.
Cancer Discovery
|
March 10, 2017
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
Akash Patnaik, Kenneth D Swanson, Eva Csizmadia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 4, 2014
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma
Markus Riester, Lillian Werner, Joaquim Bellmunt, et al.
Nature Cancer
|
January 9, 2025
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma
Tejas Jammihal, Renee Maria Saliby, Chris Labaki, et al.
Cancer Immunology Research
|
May 12, 2018
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma
Rana R McKay, Dominick Bossé, Wanling Xie, et al.
Future Oncology (London, England)
|
April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial
Nourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
Page
of 26
Search research articles
Search
Showing results (211-220 of 257) with videos related to
Sort By:
Page
of 26
Cancer Cell
|
March 12, 2021
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Kevin Bi, Meng Xiao He, Ziad Bakouny, et al.
Cancer Discovery
|
February 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Miya B Hugaboom, Lena V Wirth, Kelly Street, et al.
Molecular Cancer
|
March 16, 2024
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects
Yufei Wang, Alicia Buck, Brandon Piel, et al.
Cancer Cell
|
June 10, 2025
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Kevin Bi, Meng Xiao He, Ziad Bakouny, et al.
Cancer Discovery
|
March 10, 2017
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
Akash Patnaik, Kenneth D Swanson, Eva Csizmadia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 4, 2014
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma
Markus Riester, Lillian Werner, Joaquim Bellmunt, et al.
Nature Cancer
|
January 9, 2025
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma
Tejas Jammihal, Renee Maria Saliby, Chris Labaki, et al.
Cancer Immunology Research
|
May 12, 2018
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma
Rana R McKay, Dominick Bossé, Wanling Xie, et al.
Future Oncology (London, England)
|
April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial
Nourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
Page
of 26